Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial
Importance In retrospective studies, 68 Ga-PSMA-11 positron emission tomographic (PET)
imaging improves detection of biochemically recurrent prostate cancer compared with …
imaging improves detection of biochemically recurrent prostate cancer compared with …
Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer
Purpose: Systemic androgen-signaling inhibition added to ongoing androgen-deprivation
therapy (ADT) improved clinical outcomes in patients with nonmetastatic castration-resistant …
therapy (ADT) improved clinical outcomes in patients with nonmetastatic castration-resistant …
[HTML][HTML] Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate …
WP Fendler, S Reinhardt, H Ilhan, A Delker, G Böning… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen (PSMA).
We aimed to evaluate dosimetry, safety and efficacy of 177 Lu-PSMA-617 radioligand …
We aimed to evaluate dosimetry, safety and efficacy of 177 Lu-PSMA-617 radioligand …
[HTML][HTML] Recent advances of PET imaging in clinical radiation oncology
M Unterrainer, C Eze, H Ilhan, S Marschner… - Radiation …, 2020 - Springer
Radiotherapy and radiation oncology play a key role in the clinical management of patients
suffering from oncological diseases. In clinical routine, anatomic imaging such as contrast-…
suffering from oncological diseases. In clinical routine, anatomic imaging such as contrast-…
Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake
…, E Rushing, G Nicolas, N Schäfer, H Ilhan… - Neuro …, 2016 - academic.oup.com
Background The prognosis of patients with progressive meningioma after failure of surgery
and radiotherapy is poor. Methods We retrospectively evaluated the safety and efficacy of …
and radiotherapy is poor. Methods We retrospectively evaluated the safety and efficacy of …
[HTML][HTML] Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A …
…, R Fimmers, C Kratochwil, H Rathke, H Ilhan… - European Journal of …, 2021 - Springer
Introduction The impact of prior therapies, especially chemotherapy, on overall survival (OS)
in patients with castration-resistant prostate cancer (CRPC) receiving [ 177 Lu]Lu-PSMA-…
in patients with castration-resistant prostate cancer (CRPC) receiving [ 177 Lu]Lu-PSMA-…
First clinical results for PSMA-targeted α-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients
…, CG Stief, P Bartenstein, A Todica, H Ilhan - Journal of Nuclear …, 2021 - Soc Nuclear Med
Treatment of advanced metastatic castration-resistant prostate cancer after failure of
approved therapy options remains challenging. Prostate-specific membrane antigen (PSMA)–…
approved therapy options remains challenging. Prostate-specific membrane antigen (PSMA)–…
Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer
WP Fendler, DBP Tiega, H Ilhan… - Journal of Nuclear …, 2013 - Soc Nuclear Med
90 Y radioembolization (selective internal radiation therapy [SIRT]) is a valuable therapeutic
option for unresectable hepatic metastases arising from primary colorectal cancer. The …
option for unresectable hepatic metastases arising from primary colorectal cancer. The …
Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors
H Ilhan, A Goritschan, P Paprottka… - Journal of Nuclear …, 2015 - Soc Nuclear Med
This study analyzed the predictive value of 99m Tc-labeled macroaggregated albumin (
99m Tc-MAA) SPECT for 90 Y-labeled resin microsphere therapy (radioembolization) by …
99m Tc-MAA) SPECT for 90 Y-labeled resin microsphere therapy (radioembolization) by …
Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors
H Ilhan, S Lindner, A Todica, CC Cyran, R Tiling… - European journal of …, 2020 - Springer
Introduction PET/CT using 68 Ga-labeled somatostatin analogs (SSA) targeting somatostatin
receptors (SSR) on the cell surface of well-differentiated neuroendocrine tumors (NET) …
receptors (SSR) on the cell surface of well-differentiated neuroendocrine tumors (NET) …